Study of sotatercept for pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a new treatment called sotatercept for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrow, making the heart work harder. The goal is to see if this medicine can help improve symptoms and daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have PAH, also called Group 1 pulmonary hypertension, confirmed by a heart test (right heart catheterization).
- You must have certain types of PAH, like idiopathic (unknown cause), heritable, drug/toxin-related, or related to connective tissue disease or repaired congenital heart shunts.
- You must be on stable doses of your current PAH medications and diuretics (if you take them).
- You must have symptoms that limit your activity, such as shortness of breath (WHO functional class II or III).
- You cannot have other types of pulmonary hypertension (Groups 2, 3, 4, or 5).
- You cannot have PAH related to HIV, liver disease, schistosomiasis, or certain lung conditions (like PVOD or PCH).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This study tests a new medicine called sotatercept in Japanese children who have pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become narrow and stiff, making it harder for the heart to pump blood through them. The medicine may help improve how well their hearts and lungs work together.
This study tests whether people with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs, can safely stop taking the medication sotatercept after being on it for at least 6 months and doing well. It aims to see if those who stop can maintain their health without the drug.
This trial uses a special imaging technique (xenon MRI) to see how well the lungs are functioning in people with pulmonary arterial hypertension (PAH) who are being treated with the drug sotatercept. It aims to understand if the drug improves lung function.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.